Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBIT (2020 - 2025)

Historic EBIT for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$37.3 million.

  • Lyell Immunopharma's EBIT rose 2623.9% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$342.9 million, marking a year-over-year decrease of 5793.72%. This contributed to the annual value of -$358.8 million for FY2024, which is 4524.02% down from last year.
  • Latest data reveals that Lyell Immunopharma reported EBIT of -$37.3 million as of Q3 2025, which was up 2623.9% from -$47.1 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's EBIT peaked at -$14.8 million during Q4 2022, and registered a low of -$201.1 million during Q4 2024.
  • Its 5-year average for EBIT is -$60.5 million, with a median of -$55.6 million in 2024.
  • In the last 5 years, Lyell Immunopharma's EBIT skyrocketed by 6890.07% in 2022 and then plummeted by 30251.62% in 2023.
  • Over the past 5 years, Lyell Immunopharma's EBIT (Quarter) stood at -$47.5 million in 2021, then skyrocketed by 68.9% to -$14.8 million in 2022, then tumbled by 302.52% to -$59.5 million in 2023, then crashed by 238.02% to -$201.1 million in 2024, then soared by 81.48% to -$37.3 million in 2025.
  • Its EBIT was -$37.3 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$57.4 million in Q1 2025.